Clinical trials: Opioid Use Disorder, Moderate
Opioid Use Disorder, Opioid Use Disorder, Severe
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
- Trial name
- BISTRO (NCT07631598)
- Testing
- Standard of Care Referral, Low Threshold Buprenorphine
- Where
- 8 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Opioid Use Disorder, Opioid Use Disorder, Moderate
TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization
The primary objective of this study is to evaluate the ability of TRTME to increase initiation of MOUD outpatient treatment and MOUD knowledge in hospitalized patients with OUD deemed to be good candidates for MOUD by the UCMC…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Trial name
- TRTME (NCT07780097)
- Testing
- TRTME
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- T. John Winhusen, PhD
Opioid Use Disorder, Opioid Use Disorder, Moderate
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Trial name
- TAB (NCT06651177)
- Testing
- Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 310 people
- Sponsor
- T. John Winhusen, PhD
Opioid Use Disorder, Opioid Use Disorder, Moderate
Family-Focused Study to Support Medication for Opioid Use Disorder
The purpose of this clinical trial is to develop and test whether a text- and web-based tool called FamilyCHESS - designed for individuals with opioid use disorder (OUD) and a concerned significant other (CSO) - can help the…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Trial name
- NCT07451197
- Testing
- FamilyCHESS, Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Substance Use Disorders, Opioid Use Disorder, Severe
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community…
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
- Trial name
- EXHITENTRE (NCT04921787)
- Testing
- Low Intensity, High Intensity
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gavin Bart
Moderate to Severe Opioid Use Disorder
INDV-6001 Multiple-Dose Pharmacokinetic Study
This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).
- Trial name
- NCT06576843
- Testing
- INDV-6001, Suboxone, Sublocade
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Indivior Inc.
Moderate to Severe Opioid-use Disorder
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine.
- Trial name
- NCT04995029
- Testing
- Transmucosal Buprenorphine, Extended-release Buprenorphine
- Where
- 29 sites in United States, Canada
- Volunteers
- 785 people
- Sponsor
- Indivior Inc.
Substance Use Disorder, Opioid Use Disorder, Moderate
EXHIT ENTRE Comparative Effectiveness Trial
This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or…
- Conditions
- Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Trial name
- EXHITENTRE (NCT04345718)
- Testing
- Extended Release Buprenorphine, Treatment as Usual
- Where
- 6 sites in United States
- Volunteers
- 344 people
- Sponsor
- Gavin Bart
Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
SUBLOCADE Rapid Initiation Extension Study
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
- Trial name
- NCT04060654
- Testing
- Sublocade
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals
Primary Objective: Conduct pilot study to assess effects of brief negotiation interview (BNI) Chatbot among individuals involved in the Connecticut criminal justice system with opioid use disorder (OUD).
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
- Trial name
- BNICHAT (NCT04982627)
- Testing
- BNI Chatbot, OUD Education & Treatment Resources
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Progressive Recovery, LLC
Opioid Use Disorder, Moderate
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy
- Trial name
- NCT05251376
- Testing
- Levomethadone HCl, Methadone, Morphine Sulfate
- Sponsor
- Lyndra Inc.
Moderate to Severe Opioid Use Disorder
Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder
Opioid use disorder and opioid-related deaths are increasing across Canada. The mainstay of medical treatment includes either full (methadone) or partial (buprenorphine) opioid agonist therapy.
- Trial name
- STOPIT (NCT05594121)
- Testing
- Extended Release Subcutaneous Buprenorphine, Immediate Release Sublingual Buprenorphine
- Where
- 5 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Royal Victoria Hospital, Canada
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly…
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving
- Trial name
- CBOT-OUD (NCT04850664)
- Testing
- CBOT + TAU
- Where
- 4 sites in United States
- Volunteers
- 190 people
- Sponsor
- Evon Medics LLC
Moderate or Severe Opioid Use Disorder
A Multiple Dose Opioid Challenge Study
Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use…
- Trial name
- NCT02611752
- Testing
- CAM2038
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Braeburn Pharmaceuticals